China-headquartered WuXi XDC announced on 23 July it expects over 60% year-on-year revenue growth and 50% net profit growth for the first half of 2025, with adjusted net profit (excluding interest) surging 67%. The antibody-drug conjugate (ADC) contract research, development and manufacturing organisation (CRDMO) attributed this performance to strong downstream demand in the ADC sector, expanded market share and improved production efficiency. The company's proprietary WuXiDARx and X-LinC linker technologies supported 45 pre-clinical candidates and 7 clinical programs as of 2024.

WuXi XDC is expanding global capacity with new facilities in Wuxi, Changzhou, Shanghai and Singapore. The Singapore site will offer 2000-litre batch production capacity for antibody intermediates and commercial-scale conjugation when operational in 2026. CEO Jimmy Li highlighted opportunities in bispecific ADCs and novel payload technologies at the World ADC Asia Summit. WuXi XDC shares rose 12% to HKD 56.55 following the announcement.

According to PharmCube's NextBiopharm® database, in March this year WuXi XDC signed a memorandum of understanding with South Korea's AbTis to integrate the latter's AbClick ADC platform. Click here to request a free trial for NextBiopharm®.